Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
US Comfortable With Canada Trade Standoff as Import Bans Loom 
3 clinical-grade skincare creams you really shouldn’t buy online 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
Oura IPO Draws Strong Demand Ahead of $2.2 Billion Offering 
Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
Almonty Industries Shares Jump 8% After Stifel Sets $25 Target 
BlackBerry Shares Rise as Q2 Earnings, Revenue Beat Estimates 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Gold Holds Near $4,275 as Rising Treasury Yields Fuel Fed Rate Hike Bets 
US Backs Musk in Fight Against EU’s €120 Million X Fine 
Add as a preferred source on Google
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
